Sotabase

Career

· Research Assistant, UC Berkeley EECS Department2020–

Publications (20)

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Journal of Medicinal Chemistry · 2010
340
cited
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Journal of Medicinal Chemistry · 2016
327
cited
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Clinical Cancer Research · 2016
291
cited
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.
Journal of Medicinal Chemistry · 2013
85
cited
LARS2 Regulates Apoptosis via ROS-Mediated Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Ovarian Granulosa Cells
Oxidative Medicine and Cellular Longevity · 2022
47
cited
Genome-wide high-resolution mapping of mitotic DNA synthesis sites and common fragile sites by direct sequencing
Cell Research · 2020
44
cited
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
Journal of Medicinal Chemistry · 2009
43
cited
Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)
2010
28
cited
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
Bioorganic & Medicinal Chemistry Letters · 2011
26
cited
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Bioorganic & Medicinal Chemistry Letters · 2008
25
cited
Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents
2004
21
cited
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Bioorganic & Medicinal Chemistry Letters · 2003
21
cited
SAR of Carbon‐Linked, 2‐Substituted Purines: Synthesis and Characterization of AP23451 as a novel Bone‐Targeted Inhibitor of Src Tyrosine Kinase With In Vivo Anti‐Resorptive Activity
Chemical Biology and Drug Design · 2008
14
cited
Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)
2009
12
cited
Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.
2006
11
cited
Experimental investigation on the degradation of SiGe LNAs under different bias conditions induced by 3 MeV proton irradiation
Nuclear Engineering and Technology · 2021
3
cited
Corrigendum to “Bone-Targeted Src Kinase Inhibitors: Novel Pyrrolo- and Pyrazolopyrimidine Analogues”[Bioorg. Med. Chem. Lett. 13 (2003) 3063]
2003
1
cited
Dérivés phosphorés servant d'inhibiteurs de kinase
2009
Design and experimental study of fast response α-particle energy spectrum readout system based on 4H-SiC detector
Symposium on Novel Photoelectronic Detection Technology and Application · 2023
Metabolic Engineering of Bacillus subtilis for 2.3-BDO production by introducing an exogenous NADPH/NADP+ regeneration system
2019
Sotabase